European Prostate Cancer Virtual Support Group, March 18, 2026
Our European AnCan audience, who find it tough to attend meetings at late hours of the night, have requested a meeting at a more time-friendly hour. Unlike our other prostate groups, this meeting is open to all levels until there is a quorum to establish separate groups for different levels of prostate cancer. The meeting will start with the lowest grade, allowing men to drop out along the way.
This peer-led, free, and drop-in meeting is open to patients and care partners and will be conducted in English. It is open to all; however, Euro-based participants are given priority. This group is held on the 3rd Wednesday of each month at 2 pm Eastern/ 8 pm CET in The Barniskis Room (222-583-973) https://ancan.org/barniskis Sign up to receive a Reminder at https://ancan.org/contact-us
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Is 5 years on enzalutamide without a change too long?
Topics Discussed
Recurrence well handled by a trial immunotherapy in Germany… or was it the radiation therapy; HT French style gives little wiggle room; surgery coming up fast at Martini to address advanced diagnosis; HT is working for Brit – BUT does it need changing up?; hyperbaric treatment in Eire to address RT cystitis
treatment options at the Nuclear Medicine in Heidelberg.
AnCan – Rick sent: 12:47 PM
Dr Jonathan Epstein. Advanced Uropathology of New York 700 Stewart Ave, Suite 101 Garden City, NY 11530 Hours: Monday-Friday 9:00AM – 6:00PM P: 516-760-2037 F: 516-200-3899 jepstein@imppllc.com
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Two men recur from low levels, one younger, while a much younger man is denovo metastatic.
Topics Discussed
Fit 87 yr old seeks more treatment ideas; younger man recurs post-LDR brachy for 3+4; – cud be a NCI candidate; 3+3 comes back after 5 yrs as 4+5; PSA stays high but stable after 9 months of doublet – change docs!; Clomid causing heart issues; Long Game candidate gives update; Axumin goes AWOL; another very young Newbie with multiple 5+5 cores needs a GU MO; Gent switches care at MSKCC
Good luck John B. I must ring off for tonight, best wishes to one and all! — Alfredo
Morgan Brooke sent: 4:36 PM
Okay. I thought I was here in the first 10 minutes. I’ll be sure to join earlier next week. Thank you
Jim Marshall, Vet Support Grp. Moderator sent: 4:36 PM
Jack. – welcome to the CLUB!!!!!
Jeff Marchi – San Francisco sent: 4:38 PM
morgan too many new people today
Morgan Brooke sent: 4:38 PM
Understood
Jeff Marchi – San Francisco sent: 4:40 PM
get here 10 minutes before the meeting
Danny sent: 4:50 PM
you looking for folks to speak?
Danny sent: 4:53 PM
Jun 2022 PSA=4 (no actions taken) Nov 2025 PSA=13 Nov 2025 MRI PiRADs=5 Nov 2025 Biopsy Gleason 10 (5+5) Nov 2025 PSMA PET Local pelvic mets Nov 2025 No Genetic germline or somatic adaptations to treat Dec 2025 Started ADT (Nubeqa 1200mg + Orgovyx 120mg) daily Jan 2026 Blood Panel (PSA=0.45 T=11)
Urology: R. Jeffrey Karnes, MD Onc: Elisabeth Heath, MD RadOnc: Anne Rajkumar, MD
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Switching hormone therapy drugs and for how long is the flavor of the day.
Topics Discussed
AnCan’s poster at GU ASCO26 https://ancan.org/ancan-gu-asco26-survivorship-poster/; doing well on HT, but for how much longer; real world evidence (RWE) lawsuit between Bayer and JnJ ARSI drugs; appointment set with GU MO at Fox Chase; confusion over NCI trial eligibility; stable after 24 months of HT – should he change it up?; triplet to doublet – can he switch HT drugs; abi and cost; HCP decisions to switch drugs; best Sibley GU MO for BRCA2; Siemens Quadrant may give better PSMA images at bladder neck; NEWBIE – climbing PSA on recurrence but nothing seen
Rick – do you have a verifiable mail or phone address for Dr. Epstein so I can request a second opinion of a Fox Chase biopsy? I’ve failed on three attempts.
AnCan GU ASCO26 survivorship poster: participants strongly endorse our Groups
For release on Monday, Feb 23, 2026
AnCan Foundation strongly believes we run the best support groups available!! We can now release the first results of our 2024 AnCan Participant Survey that confirms that our participants think so too. This first batch of results is taken from almost 300 prostate cancer responses at all levels of disease.
99% of respondents would recommend AnCan Groups
66% improved Quality of Life – 83% noted reduced stress; 62% improved nutrition; 56% increased exercise
88% advocated better for themselves and AnCan influenced over half (54%) the treatment paths
47% made new friendships – AnCan’s personal favorite since this extends support well beyond our Groups
If you’re attending GU ASCO26 , please stop by our poster on Friday, Feb 27 to meet Dr. John Antonucci, discuss these astonishing results and the AnCan method, and pick up a flyer of the poster.
Evaluating the impact of virtual peer-led support groups on prostate cancer survivorship: the AnCan experience.
John Antonucci*, Boykin B. Jordan, Anita Oppong, Richard Davis
Abstract Number: 265
Poster Board Number: A23
Session Title: Poster Session B: Prostate Cancer and Urothelial Carcinoma
Date and Time: February 27, 2026, 11:30 AM-12:45 PM; 4:45 PM-5:45 PM (PST)
Background: Comprehensive prostate cancer (PCa) survivorship requires more than just clinical care, including education, psychosocial support, self-advocacy, and lifestyle guidance—needs often unmet by traditional oncology visits. Virtual peer-led support groups, such as those offered by the AnCan Foundation, offer accessible, real-time platforms for patients to share experiences, receive guidance, and foster community, regardless of geography. This study evaluates the impact of AnCan participation on factors known to be associated with a better quality of life (QOL) among PCa survivors.
Methods: A web-based survey was administered in 2024 to PCa survivors who attended or expressed interest in AnCan meetings. Respondents (N=294) provided demographic information and rated AnCan’s impact on QOL, peer support, self-advocacy, and satisfaction. Data were analyzed to assess the subjective influence of AnCan’s virtual support model on survivorship.
Results: (2021 results are in brackets for comparison.) Most respondents were in their 60s–70s (75%), highly educated (82%), and 55% had incomes over $100,000. Eighty-three percent had someone in their lives they could rely on and with whom they maintained regular contact.
Nearly all (97%) found AnCan meetings helpful for disease understanding, learning options, and well-being. Sixty-six percent reported improved QOL; 83% [50%] noted reduced stress; 62% [38%] improved nutrition; and 56% [58%] increased exercise. Satisfaction was high, with 99% recommending AnCan.
AnCan involvement enhanced self-advocacy (88%), improved patient-provider communication, and improved decision-making. Seventy percent brought information from AnCan to their providers, 49% added new providers, and 40% changed their lead provider. Over half (54%) reported that AnCan influenced their treatment path.
Socially, 55% [43%] connected with peers outside meetings, and 47% made new friendships.
Conclusions: Survey responses indicate that the AnCan virtual peer-led model, to be described in the poster, meaningfully increases patient knowledge, empowers self-advocacy, reduces stress, and fosters healthy behaviors, improving quality of life for PCa survivors. We advocate for integrating such peer support into NCCN, AUA, and ASCO survivorship guidelines.
AnCan thanks the following sponsors for making this recording possible: Novartis, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Cribriform complicates treatment decision; and we discuss NCI trial
Topics Discussed
Over-70 KP ‘Couple’ insisted on PSA against protocol and found 4+4 cancer – cribriform complicates Tx decision; recently Dx denovo Mx ‘Couple’ seeking their way; recurrence after 7 years may set up well for NCI trial; high Decipher and cribriform may point to doublet; NCI Playing the Long Game discussed – Dr. Paul rightly finds it antithetical; Natera trial result reports zero level ctDNA; leg pain after starting doublet HT; push the IHT 3 more months with diligent AS; estradiol vets defer conversation to next week; side effects of radiation treatment
Is Gallium – 68 the more sensitive recommended radioactive tracer to use for a PSMA-PET Scan? Just wondering if seeking the best tracer produces better results.
